Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Non-Current Liabilities: 2020-2025

Historic Total Non-Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to $212.5 million.

  • Arcutis Biotherapeutics' Total Non-Current Liabilities fell 24.17% to $212.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year decrease of 24.17%. This contributed to the annual value of $190.8 million for FY2024, which is 24.25% down from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Total Non-Current Liabilities is $212.5 million, which was down 0.26% from $213.1 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Total Non-Current Liabilities ranged from a high of $280.3 million in Q3 2024 and a low of $18.4 million during Q2 2021.
  • Its 3-year average for Total Non-Current Liabilities is $232.6 million, with a median of $232.5 million in 2023.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 471.69% in 2022, then fell by 24.25% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Total Non-Current Liabilities (Quarterly) stood at $110.5 million in 2021, then soared by 471.69% to $105.1 million in 2022, then reached $251.8 million in 2023, then dropped by 24.25% to $190.8 million in 2024, then decreased by 24.17% to $212.5 million in 2025.
  • Its last three reported values are $212.5 million in Q3 2025, $213.1 million for Q2 2025, and $201.1 million during Q1 2025.